Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Disease Clear all
Completed Not applicable Interventional

Network Interventions to Reduce Disparities in Living Kidney Donation

NCT05255757
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Script Intervention, Search Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 25, 2026, 9:49 AM EDT
Not yet recruiting Not applicable Interventional

Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation

NCT07072767
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Kidney Diseases, Kidney Transplant, Living Kidney Donor
Interventions
Digital education outreach intervention for kidney transplant access and human guide, Digital education outreach intervention for kidney transplant access only (unguided)
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Phase 3 Interventional

Patient-Centered Advance Care Planning

NCT00204802
View directory record Official record
Conditions
Heart Failure, Renal Failure
Interventions
Patient-Centered Advance Care Planning
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Participants With Diabetic Kidney Disease

NCT01113801
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
Interventions
LY2382770, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Etelcalcetide on CKD-MBD

NCT03960437
View directory record Official record
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
Interventions
Etelcalcetide
Drug
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 9:49 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

NCT03876769
View directory record Official record
Conditions
B-Cell Acute Lymphoblastic Leukemia
Interventions
CTL019
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 25 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572
View directory record Official record
Conditions
Acromegaly
Interventions
Lanreotide (Autogel formulation)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

NCT00648167
View directory record Official record
Conditions
Hyperphosphatemia, End-stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Phase 4 Interventional

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Zemplar (paricalcitol injection), Calcijex
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Therapies on Chronic Kidney Disease

NCT01222234
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Interventions
Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
Drug · Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 25, 2026, 9:49 AM EDT
Recruiting Not applicable Interventional

Symptom Monitoring in Hemodialysis

NCT05738330
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD), Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 25, 2026, 9:49 AM EDT
Not listed No phase listed Observational

Home With TablO outcoMEs (HOME) Registry

NCT04526301
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
15 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
San Jose, California • Victorville, California • Pittsfield, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Not applicable Interventional

Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease

NCT02145702
View directory record Official record
Conditions
Cognitive Impairment, End-Stage Renal Disease
Interventions
Aerobic Exercise, Standard Care Dialysis
Other · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 25, 2026, 9:49 AM EDT
Withdrawn No phase listed Observational

Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis

NCT02164175
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
HeRO Graft implant for dialysis access
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)

NCT02933151
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Nutritional Supplement
Dietary Supplement
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 25, 2026, 9:49 AM EDT
Completed No phase listed Observational

Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo

NCT01033201
View directory record Official record
Conditions
Lung Transplant
Interventions
Confocal imaging
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 25, 2026, 9:49 AM EDT
Completed No phase listed Observational

Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis

NCT00340119
View directory record Official record
Conditions
End Stage Renal Disease, ESRD
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 25, 2026, 9:49 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rutgers University Study of the Genetics of Kidney Disease

NCT07217535
View directory record Official record
Conditions
Kidney Disease, Kidney Disease, Chronic, Kidney Disease, End-Stage, Kidney Diseases, Kidney Diseases, Chronic, Kidney Diseases,Cystic
Interventions
Saliva sample, Health surveys
Genetic · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 9:49 AM EDT
Withdrawn Not applicable Interventional

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B

NCT03519360
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UFR-restricted dialysis, UFR-unrestricted dialysis
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ataluren (PTC124) in Hemophilia A and B

NCT00947193
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

NCT04527328
View directory record Official record
Conditions
Cognitive Impairment, End Stage Renal Disease
Interventions
AKST1210, Sham Control (No Intervention), Hemodialysis
Device · Other · Procedure
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 25, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Diuretics in Kidney Disease

NCT04542304
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
Metolazone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 25, 2026, 9:49 AM EDT
Completed Not applicable Interventional

Surprise Question in End of Life (SeQuEL) Care and the Effect of Prompting Palliative Care Consultation: End-Stage Liver Disease

NCT06400498
View directory record Official record
Conditions
End-Stage Liver Disease
Interventions
Prompted Palliative Care Consult
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 25, 2026, 9:49 AM EDT